Current federal funding levels to combat the opioid crisis do not meet the alarming demand brought on by the COVID-19 pandemic, according to a new report.
The Bipartisan Policy Center on Wednesday released a report that found federal opioid funding grew only 3.2% in fiscal year 2019, for a total of $7.6 billion.
Three-quarters of that funding went toward treatment, recovery and prevention programs in states, with the rest dedicated to law enforcement. That marks a departure from the “War on Drugs” approach taken by most states for the past 40 years that mostly involved increasing prison sentences for both drug dealers and users.
The analysis also found Medicaid coverage of medication-assisted therapies like buprenorphine and naltrexone and the opioid overdose-reversal medication naloxone grew by 15% to nearly $1.6 billion in 2019.
Source: Modern Healthcare